Login
$XLO
$7.31 -$0.26 (3.43%) Close

$XLO 4 SEC Filings

Filed On Filing
02 Oct 2026 Form 4: Houvras Yariv, CHIEF MEDICAL OFFICER

Granted 105,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Shannon James Samuel, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Bello Akintunde Olatokumbo, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Curran Daniel J., Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Xu Yuan, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Ross Robert W., Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Bonstein Sara, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Brennan Aoife, Director

Granted 5,000 Stock Option (right to buy)

16 Apr 2026 Form 4: Blanchard Cheryl R, Director

Granted 10,000 Stock Option (right to buy)

30 Mar 2026 Form 4: Shannon James Samuel, Director

Bought 5,000 shares ($44K)

17 Feb 2026 Form 4: Gilead SCIENCES, Inc., 10% owner

Acquired 3,739,000 Prefunded Warrants (right to buy) (Open Market Purchase) ($2M)

05 Jan 2026 Form 4: Luptakova Katarina, CHIEF MEDICAL OFFICER

Granted 451,885 Stock Option (right to buy) · Received 16,625 shares by exercise or conversion

05 Jan 2026 Form 4: Brennan Kevin M., SVP, FINANCE AND ACCOUNTING

Granted 95,221 Stock Option (right to buy) · Received 5,000 shares by exercise or conversion · Sold 1,826 shares ($1.17K)

05 Jan 2026 Form 4: Frankenfield Christopher James, Chief Financial Officer

Granted 668,789 Stock Option (right to buy) · Received 19,375 shares by exercise or conversion · Sold 7,030 shares ($4.52K)

05 Jan 2026 Form 4: Russo Rene, Director

Granted 1,500,258 Stock Option (right to buy) · Received 44,250 shares by exercise or conversion

01 Dec 2025 Form 4: Gilead SCIENCES, Inc., 10% owner

Acquired 13,335,000 Prefunded Warrants (right to buy) (In/At-money Exercise) ($10M) · Exercised 13,335,000 Series B Warrants (right to buy)

25 Nov 2025 Form 4: Brennan Kevin M., SVP, FINANCE AND ACCOUNTING

Granted 231,700 Stock Option (right to buy) · Disposed of 100,000 Stock Option (right to buy) (Disposition to Issuer)

25 Nov 2025 Form 4: Luptakova Katarina, CHIEF MEDICAL OFFICER

Granted 850,210 Stock Option (right to buy) · Disposed of 225,210 Stock Option (right to buy) (Disposition to Issuer)

25 Nov 2025 Form 4: Frankenfield Christopher James, Chief Financial Officer

Granted 1,618,082 Stock Option (right to buy) · Disposed of 848,172 Stock Option (right to buy) (Disposition to Issuer) · Disposed of 155,090 Stock Option (right to buy) (Grant/Award Acquisition)

25 Nov 2025 Form 4: Russo Rene, Director

Granted 4,273,212 Stock Option (right to buy) · Disposed of 2,198,212 Stock Option (right to buy) (Disposition to Issuer)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support